Carl Lindgren
Chairman of the Board since 2024. Board member since 2023. Born 1968.
More than 25 years of experience in senior commercial positions within the Life Science industry, including roles at AstraZeneca, Lundbeck, Karo Healthcare, and EQL Pharma.
Education: B.Sc., Business Administration and Economics, Lund University
Other assignments: Board member BioMedica AB, Chief Business Development Officer at EQL Pharma
Holding: 563,331 shares
Independent in relation to the Company’s major shareholders and the Company and management.
Mats Johansson
Chairman of the Board 2013-2020. Board member 2021. Born 1961.
Over 30 years of experience in founding and long-term development of companies, as well as listing companies on Nasdaq Stockholm.
Education: High School
Other assignments: Chairman of the Board, Abraxas Holding AB, Easy Depot AB, Volubus AB, and SiB Solutions AB. Board member, Klarabo Sverige AB, Nudging Capital AB.
Holding: 2,924,081 shares
Dependent in relation to the Company’s major shareholders and the Company and management.
Orest Lastow
Board member since 2013. Born 1964.
Over 30 years of experience in inhaled pharmaceuticals, has invented around 30 inhalers, including all of Iconovo’s inhalation platforms. Author of over 50 patent applications and several research articles and books.
Education: MSc, Engineering Physics, Lund University. PhD, Aerosol Physics, Brunel University, London.
Other assignments: Board member, Lastow Consulting AB.
Holding: 826,400 shares
Dependent in relation to the Company’s major shareholders and the Company and management.
Berndt Axelsson
Board member since 2013. Born 1959.
20-year background in PwC as a management consultant. Has since worked in the industry as CFO and CEO with a focus on M&A, Legal & Risk, and international distribution.
Education: BA Economics, Växjö University
Other assignments: CEO and Board member, BAN Business Consulting AB. Chairman of the Board, INVID Jönköping AB, Nässjö Näringsliv AB.
Holding: 320,000 shares
Independent in relation to the Company’s major shareholders and the Company and management.
Erik Westlund
Board member since 2025. Born 1978.
He has a solid background in real estate development and corporate finance, and is co-founder of Bolite, with prior experience from Savana, ABG, Catella, Carnegie, and Leimdörfer.
Education: Holds a M.Sc. in Business and Economics from Stockholm School of Economics with a focus on accounting and finance, and a Master of Laws (LL.M.) from Umeå University.
Other assignments: Chairman of the Board at Bolite Bostäder Holding AB. Board member of Bässkär AB, Rhestare AB, and Sjöhusen i Umeå AB. Deputy board member of Askporten AB, Bolite Bostäder Mgmt AB, Bolite Fastigheter AB, Bolite Fastigheter Holding AB, Bolite i Haninge AB, Bolite i Knivsta 2 AB, Bolite Invest AB, Bolite Utveckling 3 AB, Bolite Utveckling 4 AB, Bolite Utveckling 5 AB, Bolite Utveckling 6 AB, Bolite Utveckling AB, Furuporten AB, Kvartsporten AB, Lärkporten AB, PropLN AB, and Träporten AB.
Holding: 362,852 shares (via 50 procent ownership in Bolite Invest AB)
Independent in relation to the Company’s major shareholders and the Company and management.
Andreas Engström
Board member since 2025. Born 1973
20 years of experience in the pharmaceutical industry, both within regulatory authorities and the private sector, with a focus on pricing, reimbursement, and health economics. He is currently Director of Health Economics and Outcomes Research for Central and Northern Europe at Alexion Pharma.
Education: Holds a M. Sc. in Business and Economics from the Stockholm School of Economics.
Other assignments: Board member of Bluefish Pharmaceuticals AB (publ) and Coruscant Access Excellence AB.
Holding: 40,000 shares
Independent in relation to the Company and management, but not to the Company’s major shareholders.
Christer Fåhraeus
Board member since 2025. Born 1965.
Has 30 years of experience as CEO and board member of both listed and unlisted companies in the Life Science and Tech sectors, and is the founder of companies such as CellaVision AB, FlatFrog Laboratories AB, Anoto Group AB, Precise Biometrics AB, EQL Pharma AB, and Fåhraeus Startup and Growth AB.
Education: Holds a Bachelor and PhD in Neurophysiology from the Faculty of Medicine at Lund University, a M.Sc. in Medical Engineering from the UCSD (USA), and the equivalent of five years of full-time studies in mathematics and physics at Lund University and LTH (Engineering Physics).
Other assignments: Chairman of the Board at EQL Pharma AB, ApoEco Sverige AB, Fåhraeus Startup & Growth AB, and FSG Fund II AB. Board member of CellaVision AB, Fåhraeus Institute AB, Fårö Capital AB, Wranne Fåhraeus Design AB, Theope Seed Capital AB, FlatFrog Laboratories AB, OssDsign AB, Oncorena AB, Oncorena Holding AB, EQL Pharma Int AB, Smältan Invest AB, Checkin Group AB, Bionamic AB, and Melius Pharma AB. Deputy board member of Rapidus Media AB and CJ Scandinavian Seaview Consulting AB.
Holding: 0 shares
Independent in relation to the Company and management, but not to the Company’s major shareholders,
Follow us on Linkedin
